Viktor Grünwald, MD, PhD, discusses what findings from the post hoc analysis of the CLEAR trial of lenvatinib plus pembrolizumab vs sunitinib for patients with renal cell carcinoma mean for community oncologists.
Viktor Grünwald, MD, PhD, interdisciplinary genitourinary oncology, clinic for urology and clinic for medical oncology, University Hospital Essen, Essen, Germany, discusses what the findings from the post hoc analysis of the CLEAR trial (NCT02811861) evaluating lenvatinib (Lenvima) plus pembrolizumab (Keytruda) vs sunitinib (Sutent) for the treatment of patients with renal cell carcinoma mean for community oncologists, and what the next steps for research include.
At the 2023 ESMO Annual Congress, Grünwald presented data on tumor response by baseline metastases at the final prespecified overall survival analysis time point of July 31, 2022.
Transcription:
0:10 | When we speak about next steps, I think something that is really important is to understand really what is the delivery that a treatment has at a certain organ site? Because I think as a physician, I would like to know. I think we have a very good approximate when we use this approach with the target lesions, but I think ideally, we would look in depth into those CT scans and understand what is the tumor shrinkage, not only on the target lesions, but on overall, all lesions by 1 specific organ side. I think that would be also quite informative, but that's really an endeavor.
0:54 | The main question is really, let's say you have a patient with bone lesions. Will they benefit from this type of approach? Or should they be offered another combination? These are questions that you have once you sit in front of the patient, so what data do we have to support this? I think from this specific analysis, we have seen that lenvatinib/pembrolizumab was also quite efficacious in the bone lesions. It's in lymph nodes, lungs, and liver. I think that's quite informative. It is robust in its delivery, and I think these are the main takeaways for the everyday practice.
Key Takeaways From QOL and Use of Steroids With IO-Based RCC Regimens
May 6th 2024During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Comparing Choices for IO/TKI Combinations in Advanced RCC
May 2nd 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on the combination of immunotherapy and tyrosine kinase inhibitors for patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Sustained Treatment-Free Survival in RCC Seen With Nivolumab and Ipilimumab
April 30th 2024Nivolumab monotherapy plus salvage nivolumab/ipilimumab demonstrated superior treatment-free survival rates among patients with advanced renal cell carcinoma, especially in patients with favorable risk profiles.
Read More
Roundtable Roundup April: Renal Cell Carcinoma
April 27th 2024In separate, live virtual events, Arnab Basu, MD, MPH, and Robert J. Motzer, MD, asked participants which therapy they would choose for a patient with clear cell renal cell carcinoma (RCC) and why they would make that choice.
Read More